Caloric restriction and cancer: Molecular mechanisms and clinical implications

Trends in Molecular Medicine

Volumn 20, Issue 8, 2014, Pages 419-427

  Meynet, Ophélie ^a,b   Ricci, Jean Ehrland ^a,b,c  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

AMPK; Caloric restriction; Cancer; Chemotherapy; Immune response; MTOR

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; TARGET OF RAPAMYCIN KINASE;

ANIMAL; CALORIC RESTRICTION; DIET THERAPY; HUMAN; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; CALORIC RESTRICTION; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84905096743     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.05.001     Document Type: Review

References (96)

1. Muñoz-Pinedo C., et al. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012, 3:e248.
2. Khandekar M.J., et al. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 2011, 11:886-895.
3. Kitahara C.M., et al. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J. Clin. Oncol. 2013, 31:2450-2459.
4. Yuan C., et al. Prediagnostic body mass index and pancreatic cancer survival. J. Clin. Oncol. 2013, 31:4229-4234.
5. Willcox D.C., et al. The Okinawan diet: health implications of a low-calorie, nutrient-dense, antioxidant-rich dietary pattern low in glycemic load. J. Am. Coll. Nutr. 2009, 28:500S-516S.
6. Michels K.B., Ekbom A. Caloric restriction and incidence of breast cancer. JAMA 2004, 291:1226-1230.
7. Tannenbaum A. The genesis and growth of tumors. II. Effects of caloric restriction per se. Cancer Res. 1942, 2:460-467.
8. Weindruch R., Walford R.L. Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. Science 1982, 215:1415-1418.
9. McCay C.M., et al. The effect of retarded growth upon the length of life span and upon the ultimate body size. J. Nutr. 1935, 10:63-79.
10. Harper J.M., et al. Does caloric restriction extend life in wild mice?. Aging Cell 2006, 5:441-449.
11. Dhahbi J.M., et al. Temporal linkage between the phenotypic and genomic responses to caloric restriction. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5524-5529.
12. Colman R.J., et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:210-214.
13. Mattison J.A., et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012, 489:318-321.
14. Mukherjee P., et al. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin. Cancer Res. 2004, 10:5622-5629.
15. Marsh J., et al. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin. Cancer Res. 2008, 14:7751-7762.
16. Mulrooney T.J., et al. Influence of caloric restriction on constitutive expression of NF-κB in an experimental mouse astrocytoma. PLoS ONE 2011, 6:e18085.
17. Hursting S.D., et al. Calorie restriction and cancer prevention: a mechanistic perspective. Cancer Metab. 2013, 1:10.
18. Gallagher E.J., Leroith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011, 152:2546-2551.
19. Price A.J., et al. Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol. Biomarkers Prev. 2012, 21:1531-1541.
20. Gao Y., et al. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int. J. Cancer 2012, 131:E105-E113.
21. Levine M.E., et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab. 2014, 19:407-417.
22. Dunn S.E., et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997, 57:4667-4672.
23. Majeed N., et al. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 2005, 24:4736-4740.
24. Anzo M., et al. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res. 2008, 68:3342-3349.
25. Schmeisser K., et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat. Chem. Biol. 2013, 9:693-700.
26. Kalaany N.Y., Sabatini D.M. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009, 458:725-731.
27. Curry N.L., et al. PTEN-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. Cancer Discov. 2013, 3:908-921.
28. Johnson S.C., et al. mTOR is a key modulator of ageing and age-related disease. Nature 2013, 493:338-345.
29. Wang P., et al. Loss of AMP-activated protein kinase-α2 impairs the insulin-sensitizing effect of calorie restriction in skeletal muscle. Diabetes 2012, 61:1051-1061.
30. Leprivier G., et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013, 153:1064-1079.
31. Faubert B., et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013, 17:113-124.
32. Jeon S.M., et al. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485:661-665.
33. Chang H.C., Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab. 2014, 25:138-145.
34. Fulco M., et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev. Cell 2008, 14:661-673.
35. Yuan H., et al. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther. 2013, 6:1399-1416.
36. Bordone L., et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007, 6:759-767.
37. Herranz D., et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 2010, 1:3.
38. Firestein R., et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008, 3:e2020.
39. Chen D., et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 2008, 22:1753-1757.
40. Hallows W.C., et al. Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation. J. Biol. Chem. 2012, 287:3850-3858.
41. Finley L.W., et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 2011, 19:416-428.
42. Sebastián C., et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012, 151:1185-1199.
43. Jeong S.M., et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 2013, 23:450-463.
44. Csibi A., et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013, 153:840-854.
45. Pearson K.J., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
46. Timmers S., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14:612-622.
47. Um J.H., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59:554-563.
48. Park S.J., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
49. Knight C.M., et al. Mediobasal hypothalamic SIRT1 is essential for resveratrol's effects on insulin action in rats. Diabetes 2011, 60:2691-2700.
50. Price N.L., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15:675-690.
51. Hubbard B.P., et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339:1216-1219.
52. Pernicova I., Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 2014, 10:143-156.
53. Dowling R.J., et al. Metformin in cancer: translational challenges. J. Mol. Endocrinol. 2012, 48:R31-R43.
54. Sancak Y., et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141:290-303.
55. Ben Sahra I., et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011, 71:4366-4372.
56. Martin-Montalvo A., et al. Metformin improves healthspan and lifespan in mice. Nat. Commun. 2013, 4:2192.
57. Fang Y., et al. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab. 2013, 17:456-462.
58. Neff F., et al. Rapamycin extends murine lifespan but has limited effects on aging. J. Clin. Invest. 2013, 123:3272-3291.
59. +/- mice. Aging (Albany NY) 2012, 4:709-714.
60. Bjedov I., et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab. 2010, 11:35-46.
61. Houde V.P., et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010, 59:1338-1348.
62. Lamming D.W., et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
63. Blättler S.M., et al. Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. Cell Metab. 2012, 15:505-517.
64. Iliopoulos D., et al. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011, 71:3196-3201.
65. Shackelford D.B., et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013, 23:143-158.
66. Javeshghani S., et al. Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res. 2012, 72:6257-6267.
67. Willems L., et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012, 26:1195-1202.
68. Ben Sahra I., et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010, 70:2465-2475.
69. Cheong J.H., et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 2011, 10:2350-2362.
70. Cheng G., et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 2012, 72:2634-2644.
71. Xi H., et al. The wonders of 2-deoxy-d-glucose. IUBMB Life 2014, 66:110-121.
72. El Mjiyad N., et al. Sugar-free approaches to cancer cell killing. Oncogene 2011, 30:253-264.
73. Fendt S.M., et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013, 73:4429-4438.
74. Saleh A.D., et al. Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle 2013, 12:1955-1963.
75. Storozhuk Y., et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br. J. Cancer 2013, 108:2021-2032.
76. Zagorodna O., et al. 2-Deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines. Oncogene 2012, 31:2738-2749.
77. Vaillant F., et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013, 24:120-129.
78. Chen K., et al. Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms. J. Biol. Chem. 2011, 286:21993-22006.
79. Xu X., et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J. Pharmacol. Exp. Ther. 2012, 341:183-195.
80. Mukherjee P., et al. Differential effects of energy stress on AMPK phosphorylation and apoptosis in experimental brain tumor and normal brain. Mol. Cancer 2008, 7:37.
81. Veech R.L. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70:309-319.
82. Wang R., et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011, 35:871-882.
83. Beneteau M., et al. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20071-20076.
84. + T cell differentiation. Immunity 2012, 36:374-387.
85. Tai X., et al. Foxp3 transcription factor is proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals. Immunity 2013, 38:1116-1128.
86. + regulatory T cells. Nat. Immunol. 2013, 14:959-965.
87. Meynet O., et al. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. Blood 2013, 122:2402-2411.
88. De Lorenzo M.S., et al. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 2011, 32:1381-1387.
89. Shelton L.M., et al. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int. J. Cancer 2010, 127:2478-2485.
90. Lee C., et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 2012, 4:124ra127.
91. Longo V.D., Mattson M.P. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014, 19:181-192.
92. Lee C., et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010, 70:1564-1572.
93. Supic G., et al. Epigenetics: a new link between nutrition and cancer. Nutr. Cancer 2013, 65:781-792.
94. Li Y., et al. Epigenetic regulation of caloric restriction in aging. BMC Med. 2011, 9:98.
95. INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 2011, 32:537-544.
96. Papoutsis A.J., et al. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J. Nutr. 2010, 140:1607-1614.